Waldenstrom Macroglobulinemia clinical trials at UC Health
3 in progress, 1 open to new patients

• Safety, PK, PD, and Antitumor Activity of SNS-062 (Vecabrutinib) in B Lymphoid Cancers

  open to eligible people ages 18 years and up

  Phase 1b (Dose Escalation) in primarily CLL/SLL patients will evaluate safety and pharmacology of self-administered twice a day oral doses beginning at 25 mg/dose for 4 weeks with succeeding cohorts at escalating doses until establishing dose limiting toxicity or, recommended Phase 2 dose. Patient data will be assessed before authorizing dose escalation cohorts. Phase 2 (Cohort Expansion) will follow in cohorts using the recommended dose to explore clinical activity, safety, pharmacology of SNS-062 (vecabrutinib) as monotherapy.

  at UC Irvine UCSD

• Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

  Sorry, in progress, not accepting new patients

  This clinical trial studies blood sample markers of reproductive hormones in assessing ovarian reserve in younger patients with newly diagnosed lymphomas. Studying samples of blood from patients with cancer in the laboratory may help measure the effect of curative therapy for lymphoma on ovarian failure.

  at UCSF

• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

  Sorry, in progress, not accepting new patients

  This study evaluates ADCT-402 in patients with Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL). Patients will participate in a dose-escalation phase (Part 1) and dose expansion (Part 2). In Part 2, patients will receive the dose level identified in Part 1.

  at UCSD

Last updated: March 12, 2019